Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial mesenchymal transition by sponging miR-150-5p

The function of a new long non-coding RNA linc00673 remains unclear. While identified as an oncogenic player in non-small cell lung cancer (NSCLC), linc00673 was found to be anti-oncogenic in pancreatic ductal adenocarcinoma (PDAC). However whether linc00673 regulated malignancy and epithelial mesen...

Full description

Saved in:
Bibliographic Details
Published inMolecular cancer Vol. 16; no. 1; pp. 118 - 14
Main Authors Lu, Wei, Zhang, Honghe, Niu, Yuequn, Wu, Yongfeng, Sun, Wenjie, Li, Hongyi, Kong, Jianlu, Ding, Kefeng, Shen, Han-Ming, Wu, Han, Xia, Dajing, Wu, Yihua
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 11.07.2017
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The function of a new long non-coding RNA linc00673 remains unclear. While identified as an oncogenic player in non-small cell lung cancer (NSCLC), linc00673 was found to be anti-oncogenic in pancreatic ductal adenocarcinoma (PDAC). However whether linc00673 regulated malignancy and epithelial mesenchymal transition (EMT) has not been characterized. Cell proliferation was assessed using CCK-8 and EdU assays, and cell migration and invasion were assessed using scratch assays and transwell invasion assays. Epithelial mesenchymal transition was examined using western blot, qRT-PCR and immunofluorescence staining. Interaction between miRNA and linc00673 was determined using luciferase reporter assays. In vivo experiments were performed to assess tumor formation. In addition, the expression data of NSCLC specimens of TCGA and patient survival data were utilized to explore the prognostic significance of linc00673. In the present study, we found high linc00673 expression was associated with poor prognosis of NSCLC patients. In vitro experiments showed linc00673 knockdown reversed TGF-β induced EMT, and miR-150-5p was predicted to target linc00673 through bioinformatics tools. Overexpression of miR-150-5p suppressed lin00673's expression while inhibition of miR-150-5p led to significant upregulation of lin00673, suggesting that linc00673 could be negatively regulated by miR-150-5p, which was further confirmed by the inverse correlation between linc00673 and miR-150-5p in NSCLC patients' specimen. Furthermore, we proved that miR-150-5p could directly target linc00673 through luciferase assay, so linc00673 could sponge miR-150-5p and modulate the expression of a key EMT regulator ZEB1 indirectly. In addition, miR-150-5p inhibition abrogated linc00673 silence mediated proliferation, migration, invasion and EMT suppressing effect. Moreover, the inhibition of linc00673 significantly attenuated the tumorigenesis ability of A549 cells in vivo. We validated linc00673 as a novel oncogenic lncRNA and demonstrated the molecular mechanism by which it promotes NSCLC, which will advance our understanding of its clinical significance.
AbstractList Background The function of a new long non-coding RNA linc00673 remains unclear. While identified as an oncogenic player in non-small cell lung cancer (NSCLC), linc00673 was found to be anti-oncogenic in pancreatic ductal adenocarcinoma (PDAC). However whether linc00673 regulated malignancy and epithelial mesenchymal transition (EMT) has not been characterized. Methods Cell proliferation was assessed using CCK-8 and EdU assays, and cell migration and invasion were assessed using scratch assays and transwell invasion assays. Epithelial mesenchymal transition was examined using western blot, qRT-PCR and immunofluorescence staining. Interaction between miRNA and linc00673 was determined using luciferase reporter assays. In vivo experiments were performed to assess tumor formation. In addition, the expression data of NSCLC specimens of TCGA and patient survival data were utilized to explore the prognostic significance of linc00673. Results In the present study, we found high linc00673 expression was associated with poor prognosis of NSCLC patients. In vitro experiments showed linc00673 knockdown reversed TGF-β induced EMT, and miR-150-5p was predicted to target linc00673 through bioinformatics tools. Overexpression of miR-150-5p suppressed lin00673’s expression while inhibition of miR-150-5p led to significant upregulation of lin00673, suggesting that linc00673 could be negatively regulated by miR-150-5p, which was further confirmed by the inverse correlation between linc00673 and miR-150-5p in NSCLC patients’ specimen. Furthermore, we proved that miR-150-5p could directly target linc00673 through luciferase assay, so linc00673 could sponge miR-150-5p and modulate the expression of a key EMT regulator ZEB1 indirectly. In addition, miR-150-5p inhibition abrogated linc00673 silence mediated proliferation, migration, invasion and EMT suppressing effect. Moreover, the inhibition of linc00673 significantly attenuated the tumorigenesis ability of A549 cells in vivo. Conclusions We validated linc00673 as a novel oncogenic lncRNA and demonstrated the molecular mechanism by which it promotes NSCLC, which will advance our understanding of its clinical significance.
The function of a new long non-coding RNA linc00673 remains unclear. While identified as an oncogenic player in non-small cell lung cancer (NSCLC), linc00673 was found to be anti-oncogenic in pancreatic ductal adenocarcinoma (PDAC). However whether linc00673 regulated malignancy and epithelial mesenchymal transition (EMT) has not been characterized. Cell proliferation was assessed using CCK-8 and EdU assays, and cell migration and invasion were assessed using scratch assays and transwell invasion assays. Epithelial mesenchymal transition was examined using western blot, qRT-PCR and immunofluorescence staining. Interaction between miRNA and linc00673 was determined using luciferase reporter assays. In vivo experiments were performed to assess tumor formation. In addition, the expression data of NSCLC specimens of TCGA and patient survival data were utilized to explore the prognostic significance of linc00673. In the present study, we found high linc00673 expression was associated with poor prognosis of NSCLC patients. In vitro experiments showed linc00673 knockdown reversed TGF-β induced EMT, and miR-150-5p was predicted to target linc00673 through bioinformatics tools. Overexpression of miR-150-5p suppressed lin00673's expression while inhibition of miR-150-5p led to significant upregulation of lin00673, suggesting that linc00673 could be negatively regulated by miR-150-5p, which was further confirmed by the inverse correlation between linc00673 and miR-150-5p in NSCLC patients' specimen. Furthermore, we proved that miR-150-5p could directly target linc00673 through luciferase assay, so linc00673 could sponge miR-150-5p and modulate the expression of a key EMT regulator ZEB1 indirectly. In addition, miR-150-5p inhibition abrogated linc00673 silence mediated proliferation, migration, invasion and EMT suppressing effect. Moreover, the inhibition of linc00673 significantly attenuated the tumorigenesis ability of A549 cells in vivo. We validated linc00673 as a novel oncogenic lncRNA and demonstrated the molecular mechanism by which it promotes NSCLC, which will advance our understanding of its clinical significance.
The function of a new long non-coding RNA linc00673 remains unclear. While identified as an oncogenic player in non-small cell lung cancer (NSCLC), linc00673 was found to be anti-oncogenic in pancreatic ductal adenocarcinoma (PDAC). However whether linc00673 regulated malignancy and epithelial mesenchymal transition (EMT) has not been characterized.BACKGROUNDThe function of a new long non-coding RNA linc00673 remains unclear. While identified as an oncogenic player in non-small cell lung cancer (NSCLC), linc00673 was found to be anti-oncogenic in pancreatic ductal adenocarcinoma (PDAC). However whether linc00673 regulated malignancy and epithelial mesenchymal transition (EMT) has not been characterized.Cell proliferation was assessed using CCK-8 and EdU assays, and cell migration and invasion were assessed using scratch assays and transwell invasion assays. Epithelial mesenchymal transition was examined using western blot, qRT-PCR and immunofluorescence staining. Interaction between miRNA and linc00673 was determined using luciferase reporter assays. In vivo experiments were performed to assess tumor formation. In addition, the expression data of NSCLC specimens of TCGA and patient survival data were utilized to explore the prognostic significance of linc00673.METHODSCell proliferation was assessed using CCK-8 and EdU assays, and cell migration and invasion were assessed using scratch assays and transwell invasion assays. Epithelial mesenchymal transition was examined using western blot, qRT-PCR and immunofluorescence staining. Interaction between miRNA and linc00673 was determined using luciferase reporter assays. In vivo experiments were performed to assess tumor formation. In addition, the expression data of NSCLC specimens of TCGA and patient survival data were utilized to explore the prognostic significance of linc00673.In the present study, we found high linc00673 expression was associated with poor prognosis of NSCLC patients. In vitro experiments showed linc00673 knockdown reversed TGF-β induced EMT, and miR-150-5p was predicted to target linc00673 through bioinformatics tools. Overexpression of miR-150-5p suppressed lin00673's expression while inhibition of miR-150-5p led to significant upregulation of lin00673, suggesting that linc00673 could be negatively regulated by miR-150-5p, which was further confirmed by the inverse correlation between linc00673 and miR-150-5p in NSCLC patients' specimen. Furthermore, we proved that miR-150-5p could directly target linc00673 through luciferase assay, so linc00673 could sponge miR-150-5p and modulate the expression of a key EMT regulator ZEB1 indirectly. In addition, miR-150-5p inhibition abrogated linc00673 silence mediated proliferation, migration, invasion and EMT suppressing effect. Moreover, the inhibition of linc00673 significantly attenuated the tumorigenesis ability of A549 cells in vivo.RESULTSIn the present study, we found high linc00673 expression was associated with poor prognosis of NSCLC patients. In vitro experiments showed linc00673 knockdown reversed TGF-β induced EMT, and miR-150-5p was predicted to target linc00673 through bioinformatics tools. Overexpression of miR-150-5p suppressed lin00673's expression while inhibition of miR-150-5p led to significant upregulation of lin00673, suggesting that linc00673 could be negatively regulated by miR-150-5p, which was further confirmed by the inverse correlation between linc00673 and miR-150-5p in NSCLC patients' specimen. Furthermore, we proved that miR-150-5p could directly target linc00673 through luciferase assay, so linc00673 could sponge miR-150-5p and modulate the expression of a key EMT regulator ZEB1 indirectly. In addition, miR-150-5p inhibition abrogated linc00673 silence mediated proliferation, migration, invasion and EMT suppressing effect. Moreover, the inhibition of linc00673 significantly attenuated the tumorigenesis ability of A549 cells in vivo.We validated linc00673 as a novel oncogenic lncRNA and demonstrated the molecular mechanism by which it promotes NSCLC, which will advance our understanding of its clinical significance.CONCLUSIONSWe validated linc00673 as a novel oncogenic lncRNA and demonstrated the molecular mechanism by which it promotes NSCLC, which will advance our understanding of its clinical significance.
Abstract Background The function of a new long non-coding RNA linc00673 remains unclear. While identified as an oncogenic player in non-small cell lung cancer (NSCLC), linc00673 was found to be anti-oncogenic in pancreatic ductal adenocarcinoma (PDAC). However whether linc00673 regulated malignancy and epithelial mesenchymal transition (EMT) has not been characterized. Methods Cell proliferation was assessed using CCK-8 and EdU assays, and cell migration and invasion were assessed using scratch assays and transwell invasion assays. Epithelial mesenchymal transition was examined using western blot, qRT-PCR and immunofluorescence staining. Interaction between miRNA and linc00673 was determined using luciferase reporter assays. In vivo experiments were performed to assess tumor formation. In addition, the expression data of NSCLC specimens of TCGA and patient survival data were utilized to explore the prognostic significance of linc00673. Results In the present study, we found high linc00673 expression was associated with poor prognosis of NSCLC patients. In vitro experiments showed linc00673 knockdown reversed TGF-β induced EMT, and miR-150-5p was predicted to target linc00673 through bioinformatics tools. Overexpression of miR-150-5p suppressed lin00673’s expression while inhibition of miR-150-5p led to significant upregulation of lin00673, suggesting that linc00673 could be negatively regulated by miR-150-5p, which was further confirmed by the inverse correlation between linc00673 and miR-150-5p in NSCLC patients’ specimen. Furthermore, we proved that miR-150-5p could directly target linc00673 through luciferase assay, so linc00673 could sponge miR-150-5p and modulate the expression of a key EMT regulator ZEB1 indirectly. In addition, miR-150-5p inhibition abrogated linc00673 silence mediated proliferation, migration, invasion and EMT suppressing effect. Moreover, the inhibition of linc00673 significantly attenuated the tumorigenesis ability of A549 cells in vivo. Conclusions We validated linc00673 as a novel oncogenic lncRNA and demonstrated the molecular mechanism by which it promotes NSCLC, which will advance our understanding of its clinical significance.
ArticleNumber 118
Audience Academic
Author Niu, Yuequn
Xia, Dajing
Lu, Wei
Wu, Han
Kong, Jianlu
Wu, Yongfeng
Sun, Wenjie
Li, Hongyi
Wu, Yihua
Ding, Kefeng
Zhang, Honghe
Shen, Han-Ming
Author_xml – sequence: 1
  givenname: Wei
  surname: Lu
  fullname: Lu, Wei
– sequence: 2
  givenname: Honghe
  surname: Zhang
  fullname: Zhang, Honghe
– sequence: 3
  givenname: Yuequn
  surname: Niu
  fullname: Niu, Yuequn
– sequence: 4
  givenname: Yongfeng
  surname: Wu
  fullname: Wu, Yongfeng
– sequence: 5
  givenname: Wenjie
  surname: Sun
  fullname: Sun, Wenjie
– sequence: 6
  givenname: Hongyi
  surname: Li
  fullname: Li, Hongyi
– sequence: 7
  givenname: Jianlu
  surname: Kong
  fullname: Kong, Jianlu
– sequence: 8
  givenname: Kefeng
  surname: Ding
  fullname: Ding, Kefeng
– sequence: 9
  givenname: Han-Ming
  surname: Shen
  fullname: Shen, Han-Ming
– sequence: 10
  givenname: Han
  surname: Wu
  fullname: Wu, Han
– sequence: 11
  givenname: Dajing
  surname: Xia
  fullname: Xia, Dajing
– sequence: 12
  givenname: Yihua
  surname: Wu
  fullname: Wu, Yihua
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28697764$$D View this record in MEDLINE/PubMed
BookMark eNp1kstq3DAUhk1JaS7tA3RTDN1kUac6ti7WpjCEXgJDC6FdC1mWZxRsaSrZgXmdPmmPZzJtJrQY5IP86ZN--ZxnJz54m2WvgVwB1Px9glLSqiAgCsJrVshn2RlQwQvKZH3yqD7NzlO6IwjWgr7ITsuaSyE4Pct-LYNf5egtTGgdlrdfF3nvvCGEiyqPdjX1erTtDkmD7vvcWBz6CVmjvbEx38TQu85GPbrg3-WDWx1K5-91wirXvs3txo1r2zvd54NN1pv1Fn35GLVPbubzZpunDZ5nPsfgbgtgpGCbl9nzTvfJvnp4X2Q_Pn38fv2lWH77fHO9WBaGcTIWNakA2pIaLRkVDWhMCwCaG1lXotFAdcUkB9YSbS0DzWTZtBxMaU3H66q6yG723jboO7WJbtBxq4J2ajcR4krpODrTWyUa3NIYS4A3tNYgqWloaWswxrSm69D1Ye_aTM1gW2M9xuyPpMdfvFurVbhXjBEqBEPB5YMghp-TTaMaXJpvXnsbpqRAAqbiNSWIvn2C3oUperwqpEpeUklK-ZdaaQzgfBdwXzNL1YIBlELWcqau_kHh09rBGey-zuH80YI3j4P-SXjoMATEHjAxpBRtp4wbd-2BZtcrIGruZbXvZYU_Tc29rGY1PFl5kP9_zW9Qe_Yn
CitedBy_id crossref_primary_10_1089_cbr_2019_3294
crossref_primary_10_1007_s13205_020_02443_7
crossref_primary_10_1158_1078_0432_CCR_17_2376
crossref_primary_10_3389_fgene_2023_1222059
crossref_primary_10_1016_j_omtn_2019_06_008
crossref_primary_10_1038_s41598_022_15189_4
crossref_primary_10_5808_GI_2020_18_4_e36
crossref_primary_10_1002_jcb_29559
crossref_primary_10_1016_j_prp_2021_153569
crossref_primary_10_3892_ol_2022_13290
crossref_primary_10_1016_j_heliyon_2024_e37715
crossref_primary_10_1002_mog2_51
crossref_primary_10_1097_MPA_0000000000002136
crossref_primary_10_1016_j_aquaculture_2019_06_015
crossref_primary_10_1093_toxsci_kfy039
crossref_primary_10_1016_j_biopha_2019_109049
crossref_primary_10_1186_s12935_021_01772_8
crossref_primary_10_1177_1073274818803942
crossref_primary_10_3390_cells11152448
crossref_primary_10_1016_j_amjms_2022_12_014
crossref_primary_10_1042_BSR20211175
crossref_primary_10_1002_jgm_3133
crossref_primary_10_1186_s12935_021_02270_7
crossref_primary_10_3390_ncrna8030036
crossref_primary_10_1038_s41598_023_36485_7
crossref_primary_10_1007_s12672_022_00522_0
crossref_primary_10_1002_jcp_29251
crossref_primary_10_18632_aging_204280
crossref_primary_10_32604_oncologie_2022_027545
crossref_primary_10_1007_s11010_020_03896_3
crossref_primary_10_1016_j_bbrc_2019_09_090
crossref_primary_10_1002_cbin_11314
crossref_primary_10_1007_s11010_020_03704_y
crossref_primary_10_1021_acs_jafc_3c06104
crossref_primary_10_4103_cjop_CJOP_D_23_00076
crossref_primary_10_1007_s00109_018_1654_5
crossref_primary_10_3390_ijms20112767
crossref_primary_10_1186_s12943_019_1081_4
crossref_primary_10_3892_etm_2023_12102
crossref_primary_10_1038_s41598_021_90538_3
crossref_primary_10_1111_1759_7714_14844
crossref_primary_10_3390_ijms232112737
crossref_primary_10_1038_s41419_019_1811_y
crossref_primary_10_1016_j_bbcan_2021_188612
crossref_primary_10_3390_cancers14020439
crossref_primary_10_1080_15476286_2018_1553481
crossref_primary_10_1093_abbs_gmz110
crossref_primary_10_1002_jcb_29542
crossref_primary_10_1097_CAD_0000000000001167
crossref_primary_10_1016_j_lfs_2018_12_024
crossref_primary_10_1016_j_biopha_2018_02_099
crossref_primary_10_1089_hgtb_2019_115
crossref_primary_10_3389_fmolb_2022_923584
crossref_primary_10_1186_s12935_024_03446_7
crossref_primary_10_1186_s12979_021_00258_5
crossref_primary_10_1111_jcmm_14749
crossref_primary_10_18632_aging_205908
crossref_primary_10_2174_1566524023666230329085557
crossref_primary_10_2217_epi_2019_0382
crossref_primary_10_18632_aging_203289
crossref_primary_10_1016_j_prp_2021_153528
crossref_primary_10_1080_21655979_2021_1953210
crossref_primary_10_1093_carcin_bgz125
crossref_primary_10_1016_j_exer_2022_109034
crossref_primary_10_3892_ol_2021_12913
crossref_primary_10_1186_s12935_020_01221_y
crossref_primary_10_18632_aging_101656
crossref_primary_10_1007_s43032_022_00955_6
crossref_primary_10_1186_s13046_019_1152_9
crossref_primary_10_1016_j_mtbio_2023_100632
crossref_primary_10_62347_VRBK1334
crossref_primary_10_1186_s12890_020_01240_5
crossref_primary_10_1002_1873_3468_13698
crossref_primary_10_1016_j_omtn_2024_102363
crossref_primary_10_1007_s12094_021_02658_x
crossref_primary_10_1093_toxsci_kfy107
crossref_primary_10_1016_j_envres_2023_115942
crossref_primary_10_3389_fonc_2021_761582
crossref_primary_10_2147_IJGM_S321648
crossref_primary_10_1016_j_biopha_2020_110239
crossref_primary_10_1515_chem_2022_0259
crossref_primary_10_1093_toxres_tfab097
crossref_primary_10_1155_2020_4157606
crossref_primary_10_1007_s12010_024_04992_6
crossref_primary_10_1007_s13577_018_0206_1
crossref_primary_10_1080_15384101_2022_2154556
crossref_primary_10_1016_j_yexcr_2020_112007
crossref_primary_10_1007_s12020_019_02030_8
crossref_primary_10_1042_BSR20171667
crossref_primary_10_1186_s12967_019_2068_z
crossref_primary_10_1016_j_prp_2022_154018
crossref_primary_10_3389_fgene_2021_682904
crossref_primary_10_1007_s10815_023_02959_w
crossref_primary_10_3727_096504018X15202945197589
crossref_primary_10_3389_fgene_2021_694571
crossref_primary_10_3892_etm_2017_5172
crossref_primary_10_1016_j_prp_2020_152823
crossref_primary_10_3389_fmed_2021_761724
crossref_primary_10_1007_s00018_025_05602_2
crossref_primary_10_3390_cells8101162
crossref_primary_10_1042_BSR20200390
crossref_primary_10_1016_j_omto_2019_08_010
crossref_primary_10_3892_ijo_2018_4524
crossref_primary_10_2174_1568009621666210203110305
crossref_primary_10_1002_jcb_27099
crossref_primary_10_1097_MD_0000000000033192
crossref_primary_10_3892_ol_2020_11754
crossref_primary_10_1111_cns_13152
crossref_primary_10_1016_j_biopha_2021_112360
crossref_primary_10_1016_j_biopha_2019_109457
crossref_primary_10_3389_fgene_2022_1069112
crossref_primary_10_3390_cancers12051245
crossref_primary_10_1111_cpr_12406
crossref_primary_10_1111_cas_14509
crossref_primary_10_1186_s12943_017_0716_6
crossref_primary_10_1080_21655979_2021_2012402
crossref_primary_10_1186_s12935_023_03105_3
crossref_primary_10_14712_fb2022068010016
crossref_primary_10_1038_s41419_023_05840_x
crossref_primary_10_3390_jpm11060468
crossref_primary_10_1080_21655979_2022_2053802
crossref_primary_10_3389_fonc_2021_761979
crossref_primary_10_1002_jgm_3099
crossref_primary_10_1016_j_gene_2018_12_077
crossref_primary_10_1186_s10020_022_00561_x
crossref_primary_10_1016_j_jhazmat_2023_131288
crossref_primary_10_1007_s10620_020_06691_8
crossref_primary_10_2147_COPD_S400985
crossref_primary_10_1038_s41419_019_1948_8
crossref_primary_10_1016_j_celrep_2019_04_101
crossref_primary_10_3389_fonc_2022_911613
crossref_primary_10_1038_s41419_018_0962_6
crossref_primary_10_1007_s11064_021_03311_3
crossref_primary_10_1016_j_prp_2019_01_017
crossref_primary_10_1139_bcb_2019_0065
crossref_primary_10_1111_jcmm_14883
crossref_primary_10_1016_j_bcp_2020_114095
crossref_primary_10_1016_j_lfs_2019_117134
crossref_primary_10_18632_aging_101920
crossref_primary_10_3389_fonc_2021_756148
crossref_primary_10_1002_jcla_22930
crossref_primary_10_1007_s10867_023_09633_3
crossref_primary_10_1007_s00018_020_03691_9
crossref_primary_10_3389_fgene_2022_959456
crossref_primary_10_1186_s13046_020_01819_0
crossref_primary_10_1007_s12011_023_03738_5
crossref_primary_10_1016_j_biopha_2022_112788
crossref_primary_10_1002_jcb_28973
crossref_primary_10_1038_s41419_020_2409_0
crossref_primary_10_1186_s13046_019_1421_7
crossref_primary_10_3233_CBM_230154
crossref_primary_10_1016_j_canlet_2024_217153
crossref_primary_10_1007_s10620_020_06690_9
crossref_primary_10_3389_fimmu_2022_878740
crossref_primary_10_3389_fonc_2020_01546
crossref_primary_10_3892_etm_2020_8518
crossref_primary_10_1016_j_biopha_2019_109495
crossref_primary_10_1016_j_bbrc_2018_09_191
crossref_primary_10_1007_s11060_021_03836_1
crossref_primary_10_1002_jcb_29635
crossref_primary_10_3390_ijms21041193
crossref_primary_10_1002_jcb_26802
crossref_primary_10_1007_s13402_021_00602_3
crossref_primary_10_1016_j_omtn_2019_10_031
crossref_primary_10_1089_cbr_2019_3363
crossref_primary_10_1080_1354750X_2023_2269320
crossref_primary_10_1016_j_cyto_2020_155286
crossref_primary_10_3389_fgene_2020_00929
crossref_primary_10_2147_OTT_S261973
crossref_primary_10_3390_ncrna6030025
crossref_primary_10_1016_j_ijbiomac_2022_02_094
crossref_primary_10_1016_j_biopha_2022_112963
crossref_primary_10_1038_s41598_025_85793_7
crossref_primary_10_1186_s13578_019_0302_2
crossref_primary_10_18632_aging_204426
crossref_primary_10_3389_fgene_2022_889530
crossref_primary_10_1016_j_canlet_2024_217093
crossref_primary_10_1038_s41420_022_01276_y
crossref_primary_10_1002_cbin_11270
crossref_primary_10_3892_ol_2021_13173
crossref_primary_10_1007_s12010_022_03855_2
crossref_primary_10_1016_j_prp_2023_155015
crossref_primary_10_1080_08916934_2023_2250099
crossref_primary_10_3390_ijms24021310
crossref_primary_10_26508_lsa_202302408
crossref_primary_10_1007_s10142_024_01403_1
crossref_primary_10_1186_s13046_022_02453_8
crossref_primary_10_1186_s12943_018_0870_5
crossref_primary_10_1038_s41420_021_00407_1
crossref_primary_10_1038_s41419_019_1332_8
crossref_primary_10_3390_pharmaceutics13010009
crossref_primary_10_1073_pnas_1900997116
crossref_primary_10_1038_s41401_021_00655_y
crossref_primary_10_1155_2022_2485055
crossref_primary_10_1111_jcmm_18247
crossref_primary_10_3892_ijo_2019_4734
crossref_primary_10_1016_j_bbrc_2017_12_047
crossref_primary_10_3389_fonc_2021_690641
crossref_primary_10_1038_s41388_019_0904_5
crossref_primary_10_1089_cbr_2019_3259
crossref_primary_10_1016_j_toxlet_2019_11_024
crossref_primary_10_1007_s00432_020_03161_6
Cites_doi 10.1007/s13277-015-4073-z
10.1136/jmedgenet-2015-103334
10.1038/nature05874
10.1016/j.ccr.2014.03.010
10.1093/carcin/bgs381
10.1158/0008-5472.CAN-10-4554
10.1016/j.jmb.2013.02.030
10.1074/jbc.M116.750950
10.1038/bjc.2014.383
10.1002/ijc.29210
10.1016/j.cell.2011.07.014
10.18632/oncotarget.5728
10.1016/j.cell.2009.11.007
10.1007/s13277-014-2150-3
10.1002/jso.23648
10.18632/oncotarget.8338
10.1038/cdd.2013.123
10.3322/caac.21332
10.1038/onc.2015.223
10.18632/oncotarget.8063
10.18632/oncotarget.4154
10.1016/j.cell.2009.02.006
10.1002/cbf.3079
10.1016/j.canlet.2015.11.043
10.1097/JTO.0000000000000470
10.1016/j.ccr.2009.03.016
10.3322/caac.21235
10.1097/MPA.0000000000000333
10.1615/CritRevOncog.2014011802
10.5507/bp.2012.049
10.1159/000147748
10.1016/j.cell.2011.09.032
10.1111/cas.12030
10.18632/oncotarget.7292
10.1080/15476286.2015.1063770
10.1158/0008-5472.CAN-14-2931
10.5487/TR.2010.26.4.245
10.1038/nature11233
10.1016/j.cell.2011.09.028
10.1038/sj.bjc.6605530
10.1158/1078-0432.CCR-13-1455
10.1002/stem.1448
10.1038/onc.2015.366
10.18632/oncotarget.12995
10.1097/JTO.0b013e318283d958
10.1080/15384101.2015.1006048
10.1016/j.tig.2011.06.001
10.1016/j.canlet.2016.02.018
10.1016/j.ccell.2016.03.004
10.1093/annonc/mdv318
10.1101/gr.082701.108
10.1158/0008-5472.CAN-14-3721
ContentType Journal Article
Copyright COPYRIGHT 2017 BioMed Central Ltd.
Copyright BioMed Central 2017
The Author(s). 2017
Copyright_xml – notice: COPYRIGHT 2017 BioMed Central Ltd.
– notice: Copyright BioMed Central 2017
– notice: The Author(s). 2017
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TO
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12943-017-0685-9
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
AUTh Library subscriptions: ProQuest Central
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic
ProQuest Publicly Available Content
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database
MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1476-4598
EndPage 14
ExternalDocumentID oai_doaj_org_article_7b560cce016b48a194cb42e81cccdcff
PMC5504775
A511279899
28697764
10_1186_s12943_017_0685_9
Genre Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: ;
  grantid: 31471297
– fundername: ;
  grantid: 81400371; 81302455
GroupedDBID ---
0R~
123
29M
2WC
53G
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACMJI
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EJD
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
H13
HH5
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
PZZ
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
-A0
3V.
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
FRP
NPM
PMFND
7TO
7XB
8FK
AHSBF
AZQEC
DWQXO
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c560t-80311d24ca9547b1a017111a6c9837ba14a359615d0aee51a592bd61c2ecf6833
IEDL.DBID M48
ISSN 1476-4598
IngestDate Wed Aug 27 01:22:58 EDT 2025
Thu Aug 21 14:12:11 EDT 2025
Fri Jul 11 05:20:49 EDT 2025
Fri Jul 25 20:03:48 EDT 2025
Tue Jun 17 21:49:29 EDT 2025
Tue Jun 10 20:08:39 EDT 2025
Wed Feb 19 02:41:09 EST 2025
Thu Apr 24 23:01:37 EDT 2025
Tue Jul 01 01:01:14 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords linc00673
Epithelial mesenchymal transition
miR-150-5p
Competing endogenous RNA
Non-small cell lung cancer
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c560t-80311d24ca9547b1a017111a6c9837ba14a359615d0aee51a592bd61c2ecf6833
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12943-017-0685-9
PMID 28697764
PQID 1926249029
PQPubID 42702
PageCount 14
ParticipantIDs doaj_primary_oai_doaj_org_article_7b560cce016b48a194cb42e81cccdcff
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5504775
proquest_miscellaneous_1918376840
proquest_journals_1926249029
gale_infotracmisc_A511279899
gale_infotracacademiconefile_A511279899
pubmed_primary_28697764
crossref_citationtrail_10_1186_s12943_017_0685_9
crossref_primary_10_1186_s12943_017_0685_9
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2017-07-11
PublicationDateYYYYMMDD 2017-07-11
PublicationDate_xml – month: 07
  year: 2017
  text: 2017-07-11
  day: 11
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Molecular cancer
PublicationTitleAlternate Mol Cancer
PublicationYear 2017
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References L Zhang (685_CR50) 2013; 34
L Salmena (685_CR25) 2011; 146
CE DeSantis (685_CR9) 2014; 64
J Ferlay (685_CR10) 2015; 136
M Cesana (685_CR26) 2011; 147
E Rulli (685_CR44) 2015; 26
JH Yuan (685_CR18) 2014; 25
L Qu (685_CR28) 2016; 29
A Barbachano (685_CR38) 2016; 35
D Han (685_CR51) 2016; 7
L Ombrato (685_CR11) 2014; 19
E Birney (685_CR3) 2007; 447
Y Wu (685_CR17) 2009; 15
RL Siegel (685_CR53) 2016; 66
CP Ponting (685_CR8) 2009; 136
Y Wu (685_CR16) 2010; 102
B Santosh (685_CR2) 2015; 33
M Jin (685_CR35) 2014; 9
Q Ji (685_CR34) 2014; 111
T Yokobori (685_CR37) 2013; 104
E Sanchez-Tillo (685_CR40) 2014; 21
P Han (685_CR7) 2015; 12
H Hirata (685_CR32) 2015; 75
W Sun (685_CR43) 2016; 7
X Qi (685_CR52) 2015; 52
P Martin (685_CR47) 2013; 8
Z Luo (685_CR36) 2013; 31
Y Fan (685_CR19) 2014; 20
T Li (685_CR20) 2016; 35
K Yang (685_CR42) 2015; 44
ED Hay (685_CR12) 1995; 154
WC Liang (685_CR30) 2015; 6
D Wang (685_CR33) 2015; 6
M Gachechiladze (685_CR46) 2012; 156
S Djebali (685_CR1) 2012; 489
T Li (685_CR39) 2015; 75
P Zhang (685_CR54) 2015; 14
H Jiang (685_CR48) 2014; 35
AC Tuck (685_CR5) 2011; 27
685_CR24
Q Liu (685_CR23) 2016; 37
IV Novikova (685_CR6) 2013; 425
SP Li (685_CR29) 2016; 7
JM Donahue (685_CR45) 2014; 110
JP Thiery (685_CR13) 2009; 139
X Chen (685_CR21) 2016; 7
M Terashima (685_CR22) 2017; 292
J Tang (685_CR31) 2016; 371
H Yu (685_CR49) 2015; 10
RC Friedman (685_CR4) 2009; 19
MK Asiedu (685_CR15) 2011; 71
FA Karreth (685_CR27) 2011; 147
HX Zhan (685_CR41) 2016; 374
H Son (685_CR14) 2010; 26
26683775 - Cancer Lett. 2016 Feb 28;371(2):301-13
23069884 - Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012 Sep;156(3):200-3
22000016 - Cell. 2011 Oct 14;147(2):382-95
27285757 - Oncotarget. 2016 Jul 5;7(27):42431-42446
24895315 - J Surg Oncol. 2014 Aug;110(2):97-8
24449823 - Clin Cancer Res. 2014 Mar 15;20(6):1531-41
24278531 - Toxicol Res. 2010 Dec;26(4):245-52
26358722 - J Med Genet. 2015 Oct;52(10 ):710-8
25600645 - Cancer Res. 2015 Apr 1;75(7):1322-31
19239885 - Cell. 2009 Feb 20;136(4):629-41
26871477 - Oncotarget. 2016 Mar 8;7(10):11595-608
23765923 - Stem Cells. 2013 Sep;31(9):1749-62
26898939 - Cancer Lett. 2016 May 1;374(2):261-71
25090005 - PLoS One. 2014 Aug 04;9(8):e103965
26068968 - Oncotarget. 2015 Sep 8;6(26):22513-25
26073087 - Oncogene. 2016 Mar 24;35(12 ):1575-84
23467124 - J Mol Biol. 2013 Oct 9;425(19):3731-46
20087353 - Br J Cancer. 2010 Feb 16;102(4):639-44
24890451 - CA Cancer J Clin. 2014 Jul-Aug;64(4):252-71
21555371 - Cancer Res. 2011 Jul 1;71(13):4707-19
23222811 - Carcinogenesis. 2013 Mar;34(3):577-86
8714286 - Acta Anat (Basel). 1995;154(1):8-20
25475931 - Cell Biochem Funct. 2015 Jan;33(1):14-22
26177256 - RNA Biol. 2015;12(10):1094-8
19945376 - Cell. 2009 Nov 25;139(5):871-90
19411070 - Cancer Cell. 2009 May 5;15(5):416-28
25590602 - J Thorac Oncol. 2015 Apr;10(4):645-54
27806322 - Oncotarget. 2016 Dec 20;7(51):84480-84485
27852821 - J Biol Chem. 2017 Jan 6;292(1):82-99
25220842 - Int J Cancer. 2015 Mar 1;136(5):E359-86
26455323 - Oncogene. 2016 Jun 9;35(23):2991-3003
21802130 - Cell. 2011 Aug 5;146(3):353-8
27117758 - Cancer Cell. 2016 May 9;29(5):653-68
25607528 - Cell Cycle. 2015 ;14 (4):481-7
23524403 - J Thorac Oncol. 2013 May;8(5):530-42
27027352 - Oncotarget. 2016 May 3;7(18):25558-75
28851432 - Mol Cancer. 2017 Aug 29;16(1):144
21741109 - Trends Genet. 2011 Oct;27(10):422-32
24013721 - Cell Death Differ. 2014 Feb;21(2):247-57
18955434 - Genome Res. 2009 Jan;19(1):92-105
26742998 - CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
26989025 - Oncotarget. 2016 Apr 19;7(16):22159-73
26209642 - Ann Oncol. 2015 Oct;26(10):2079-84
24768205 - Cancer Cell. 2014 May 12;25(5):666-81
26516927 - Oncotarget. 2015 Dec 1;6(38):41045-55
22000014 - Cell. 2011 Oct 14;147(2):358-69
26069248 - Cancer Res. 2015 Aug 1;75(15):3181-91
23013135 - Cancer Sci. 2013 Jan;104(1):48-54
25522282 - Pancreas. 2015 Apr;44(3):370-9
25404150 - Crit Rev Oncog. 2014;19(5):349-61
26404132 - Tumour Biol. 2016 Feb;37(2):2665-72
24913707 - Tumour Biol. 2014 Aug;35(8):7383-9
17571346 - Nature. 2007 Jun 14;447(7146):799-816
25025966 - Br J Cancer. 2014 Aug 12;111(4):736-48
22955620 - Nature. 2012 Sep 6;489(7414):101-8
References_xml – volume: 37
  start-page: 2665
  year: 2016
  ident: 685_CR23
  publication-title: Tumour Biol
  doi: 10.1007/s13277-015-4073-z
– volume: 52
  start-page: 710
  year: 2015
  ident: 685_CR52
  publication-title: J Med Genet
  doi: 10.1136/jmedgenet-2015-103334
– volume: 447
  start-page: 799
  year: 2007
  ident: 685_CR3
  publication-title: Nature
  doi: 10.1038/nature05874
– volume: 25
  start-page: 666
  year: 2014
  ident: 685_CR18
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2014.03.010
– volume: 34
  start-page: 577
  year: 2013
  ident: 685_CR50
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/bgs381
– volume: 71
  start-page: 4707
  year: 2011
  ident: 685_CR15
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-10-4554
– volume: 425
  start-page: 3731
  year: 2013
  ident: 685_CR6
  publication-title: J Mol Biol
  doi: 10.1016/j.jmb.2013.02.030
– volume: 292
  start-page: 82
  year: 2017
  ident: 685_CR22
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M116.750950
– volume: 111
  start-page: 736
  year: 2014
  ident: 685_CR34
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2014.383
– volume: 136
  start-page: E359
  year: 2015
  ident: 685_CR10
  publication-title: Int J Cancer
  doi: 10.1002/ijc.29210
– volume: 146
  start-page: 353
  year: 2011
  ident: 685_CR25
  publication-title: Cell
  doi: 10.1016/j.cell.2011.07.014
– volume: 6
  start-page: 41045
  year: 2015
  ident: 685_CR33
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.5728
– volume: 139
  start-page: 871
  year: 2009
  ident: 685_CR13
  publication-title: Cell
  doi: 10.1016/j.cell.2009.11.007
– volume: 35
  start-page: 7383
  year: 2014
  ident: 685_CR48
  publication-title: Tumour Biol
  doi: 10.1007/s13277-014-2150-3
– volume: 110
  start-page: 97
  year: 2014
  ident: 685_CR45
  publication-title: J Surg Oncol
  doi: 10.1002/jso.23648
– ident: 685_CR24
  doi: 10.18632/oncotarget.8338
– volume: 21
  start-page: 247
  year: 2014
  ident: 685_CR40
  publication-title: Cell Death Differ
  doi: 10.1038/cdd.2013.123
– volume: 66
  start-page: 7
  year: 2016
  ident: 685_CR53
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21332
– volume: 35
  start-page: 1575
  year: 2016
  ident: 685_CR20
  publication-title: Oncogene
  doi: 10.1038/onc.2015.223
– volume: 7
  start-page: 22159
  year: 2016
  ident: 685_CR51
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.8063
– volume: 6
  start-page: 22513
  year: 2015
  ident: 685_CR30
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.4154
– volume: 136
  start-page: 629
  year: 2009
  ident: 685_CR8
  publication-title: Cell
  doi: 10.1016/j.cell.2009.02.006
– volume: 33
  start-page: 14
  year: 2015
  ident: 685_CR2
  publication-title: Cell Biochem Funct
  doi: 10.1002/cbf.3079
– volume: 371
  start-page: 301
  year: 2016
  ident: 685_CR31
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2015.11.043
– volume: 10
  start-page: 645
  year: 2015
  ident: 685_CR49
  publication-title: J Thorac Oncol
  doi: 10.1097/JTO.0000000000000470
– volume: 15
  start-page: 416
  year: 2009
  ident: 685_CR17
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2009.03.016
– volume: 64
  start-page: 252
  year: 2014
  ident: 685_CR9
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21235
– volume: 44
  start-page: 370
  year: 2015
  ident: 685_CR42
  publication-title: Pancreas
  doi: 10.1097/MPA.0000000000000333
– volume: 7
  start-page: 42431
  year: 2016
  ident: 685_CR29
  publication-title: Oncotarget
– volume: 19
  start-page: 349
  year: 2014
  ident: 685_CR11
  publication-title: Crit Rev Oncog
  doi: 10.1615/CritRevOncog.2014011802
– volume: 156
  start-page: 200
  year: 2012
  ident: 685_CR46
  publication-title: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
  doi: 10.5507/bp.2012.049
– volume: 154
  start-page: 8
  year: 1995
  ident: 685_CR12
  publication-title: Acta Anat (Basel)
  doi: 10.1159/000147748
– volume: 147
  start-page: 382
  year: 2011
  ident: 685_CR27
  publication-title: Cell
  doi: 10.1016/j.cell.2011.09.032
– volume: 104
  start-page: 48
  year: 2013
  ident: 685_CR37
  publication-title: Cancer Sci
  doi: 10.1111/cas.12030
– volume: 7
  start-page: 11595
  year: 2016
  ident: 685_CR43
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.7292
– volume: 12
  start-page: 1094
  year: 2015
  ident: 685_CR7
  publication-title: RNA Biol
  doi: 10.1080/15476286.2015.1063770
– volume: 75
  start-page: 1322
  year: 2015
  ident: 685_CR32
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-14-2931
– volume: 26
  start-page: 245
  year: 2010
  ident: 685_CR14
  publication-title: Toxicol Res
  doi: 10.5487/TR.2010.26.4.245
– volume: 489
  start-page: 101
  year: 2012
  ident: 685_CR1
  publication-title: Nature
  doi: 10.1038/nature11233
– volume: 147
  start-page: 358
  year: 2011
  ident: 685_CR26
  publication-title: Cell
  doi: 10.1016/j.cell.2011.09.028
– volume: 102
  start-page: 639
  year: 2010
  ident: 685_CR16
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6605530
– volume: 20
  start-page: 1531
  year: 2014
  ident: 685_CR19
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-13-1455
– volume: 31
  start-page: 1749
  year: 2013
  ident: 685_CR36
  publication-title: Stem Cells
  doi: 10.1002/stem.1448
– volume: 35
  start-page: 2991
  year: 2016
  ident: 685_CR38
  publication-title: Oncogene
  doi: 10.1038/onc.2015.366
– volume: 7
  start-page: 84480
  year: 2016
  ident: 685_CR21
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.12995
– volume: 8
  start-page: 530
  year: 2013
  ident: 685_CR47
  publication-title: J Thorac Oncol
  doi: 10.1097/JTO.0b013e318283d958
– volume: 14
  start-page: 481
  year: 2015
  ident: 685_CR54
  publication-title: Cell Cycle
  doi: 10.1080/15384101.2015.1006048
– volume: 27
  start-page: 422
  year: 2011
  ident: 685_CR5
  publication-title: Trends Genet
  doi: 10.1016/j.tig.2011.06.001
– volume: 374
  start-page: 261
  year: 2016
  ident: 685_CR41
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2016.02.018
– volume: 29
  start-page: 653
  year: 2016
  ident: 685_CR28
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2016.03.004
– volume: 26
  start-page: 2079
  year: 2015
  ident: 685_CR44
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdv318
– volume: 9
  year: 2014
  ident: 685_CR35
  publication-title: PLoS One
– volume: 19
  start-page: 92
  year: 2009
  ident: 685_CR4
  publication-title: Genome Res
  doi: 10.1101/gr.082701.108
– volume: 75
  start-page: 3181
  year: 2015
  ident: 685_CR39
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-14-3721
– reference: 26209642 - Ann Oncol. 2015 Oct;26(10):2079-84
– reference: 25600645 - Cancer Res. 2015 Apr 1;75(7):1322-31
– reference: 25522282 - Pancreas. 2015 Apr;44(3):370-9
– reference: 27852821 - J Biol Chem. 2017 Jan 6;292(1):82-99
– reference: 25404150 - Crit Rev Oncog. 2014;19(5):349-61
– reference: 24890451 - CA Cancer J Clin. 2014 Jul-Aug;64(4):252-71
– reference: 24895315 - J Surg Oncol. 2014 Aug;110(2):97-8
– reference: 21802130 - Cell. 2011 Aug 5;146(3):353-8
– reference: 20087353 - Br J Cancer. 2010 Feb 16;102(4):639-44
– reference: 27285757 - Oncotarget. 2016 Jul 5;7(27):42431-42446
– reference: 21741109 - Trends Genet. 2011 Oct;27(10):422-32
– reference: 22955620 - Nature. 2012 Sep 6;489(7414):101-8
– reference: 25607528 - Cell Cycle. 2015 ;14 (4):481-7
– reference: 24768205 - Cancer Cell. 2014 May 12;25(5):666-81
– reference: 19239885 - Cell. 2009 Feb 20;136(4):629-41
– reference: 25025966 - Br J Cancer. 2014 Aug 12;111(4):736-48
– reference: 26068968 - Oncotarget. 2015 Sep 8;6(26):22513-25
– reference: 26069248 - Cancer Res. 2015 Aug 1;75(15):3181-91
– reference: 22000014 - Cell. 2011 Oct 14;147(2):358-69
– reference: 23467124 - J Mol Biol. 2013 Oct 9;425(19):3731-46
– reference: 22000016 - Cell. 2011 Oct 14;147(2):382-95
– reference: 28851432 - Mol Cancer. 2017 Aug 29;16(1):144
– reference: 27117758 - Cancer Cell. 2016 May 9;29(5):653-68
– reference: 25090005 - PLoS One. 2014 Aug 04;9(8):e103965
– reference: 19411070 - Cancer Cell. 2009 May 5;15(5):416-28
– reference: 23013135 - Cancer Sci. 2013 Jan;104(1):48-54
– reference: 23069884 - Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012 Sep;156(3):200-3
– reference: 18955434 - Genome Res. 2009 Jan;19(1):92-105
– reference: 24278531 - Toxicol Res. 2010 Dec;26(4):245-52
– reference: 26455323 - Oncogene. 2016 Jun 9;35(23):2991-3003
– reference: 19945376 - Cell. 2009 Nov 25;139(5):871-90
– reference: 24013721 - Cell Death Differ. 2014 Feb;21(2):247-57
– reference: 26898939 - Cancer Lett. 2016 May 1;374(2):261-71
– reference: 23765923 - Stem Cells. 2013 Sep;31(9):1749-62
– reference: 26871477 - Oncotarget. 2016 Mar 8;7(10):11595-608
– reference: 26742998 - CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
– reference: 25475931 - Cell Biochem Funct. 2015 Jan;33(1):14-22
– reference: 27027352 - Oncotarget. 2016 May 3;7(18):25558-75
– reference: 21555371 - Cancer Res. 2011 Jul 1;71(13):4707-19
– reference: 26404132 - Tumour Biol. 2016 Feb;37(2):2665-72
– reference: 26073087 - Oncogene. 2016 Mar 24;35(12 ):1575-84
– reference: 26989025 - Oncotarget. 2016 Apr 19;7(16):22159-73
– reference: 26177256 - RNA Biol. 2015;12(10):1094-8
– reference: 24449823 - Clin Cancer Res. 2014 Mar 15;20(6):1531-41
– reference: 25590602 - J Thorac Oncol. 2015 Apr;10(4):645-54
– reference: 17571346 - Nature. 2007 Jun 14;447(7146):799-816
– reference: 26516927 - Oncotarget. 2015 Dec 1;6(38):41045-55
– reference: 8714286 - Acta Anat (Basel). 1995;154(1):8-20
– reference: 26358722 - J Med Genet. 2015 Oct;52(10 ):710-8
– reference: 24913707 - Tumour Biol. 2014 Aug;35(8):7383-9
– reference: 27806322 - Oncotarget. 2016 Dec 20;7(51):84480-84485
– reference: 23222811 - Carcinogenesis. 2013 Mar;34(3):577-86
– reference: 26683775 - Cancer Lett. 2016 Feb 28;371(2):301-13
– reference: 25220842 - Int J Cancer. 2015 Mar 1;136(5):E359-86
– reference: 23524403 - J Thorac Oncol. 2013 May;8(5):530-42
SSID ssj0017874
Score 2.6016502
Snippet The function of a new long non-coding RNA linc00673 remains unclear. While identified as an oncogenic player in non-small cell lung cancer (NSCLC), linc00673...
Background The function of a new long non-coding RNA linc00673 remains unclear. While identified as an oncogenic player in non-small cell lung cancer (NSCLC),...
Abstract Background The function of a new long non-coding RNA linc00673 remains unclear. While identified as an oncogenic player in non-small cell lung cancer...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 118
SubjectTerms Adenocarcinoma
Apoptosis - genetics
Base Sequence
Bioinformatics
Biomarkers
Cancer therapies
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Non-Small-Cell Lung - pathology
Cell cycle
Cell growth
Cell Line, Tumor
Cell migration
Cell Movement - genetics
Cell proliferation
Cell Proliferation - genetics
Cell Survival - genetics
Cholecystokinin
Colorectal cancer
Competing endogenous RNA
Deoxyribonucleic acid
Development and progression
DNA
Epigenetics
Epithelial mesenchymal transition
Epithelial-Mesenchymal Transition - genetics
Esophagus
Gene Expression Regulation, Neoplastic
Genetic aspects
Humans
Immunofluorescence
linc00673
Liver cancer
Lung cancer
Lung cancer, Non-small cell
Lung Neoplasms - genetics
Lung Neoplasms - pathology
Malignancy
Medical prognosis
Mesenchyme
Metastasis
MicroRNA
MicroRNAs - genetics
MicroRNAs - metabolism
miR-150-5p
miRNA
Models, Biological
Neoplasm Invasiveness
Non-coding RNA
Non-small cell lung cancer
Non-small cell lung carcinoma
Pancreas
Pancreatic cancer
Physiological aspects
Polymerase chain reaction
Prognosis
RNA, Long Noncoding - genetics
RNA, Long Noncoding - metabolism
Studies
Survival Analysis
Transforming growth factors
Tumorigenesis
Zinc Finger E-box-Binding Homeobox 1 - genetics
Zinc Finger E-box-Binding Homeobox 1 - metabolism
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9swEBejsLGXsXVfXruhwWAwZmrJkmw_ZmOljLUPZYW-CekstwHHCUk6yL-zv7R3shNiBtvLXoKJJKOPn-53Z53uGPvQNFlAkZelTuGPqmWdIgmHtDFQi8Zo4WPOyPMLc3alvl_r671UX-QT1ocH7ifupPDIyQABVROvSoc2N3glQykAoIamIemLnLc1pobzA4ShGs4wRWlOVshqivyGyNWr1Gk1YqEYrP9PkbzHSWN_yT0COn3KngyaI5_0PX7GHoTukD3sc0luDtmj8-GU_Dn7_WPe3XC061OYEzXxy4sJR3USYr4YvuzTz4c6VlnNXNty-n7PW9z4HAgGS76gbD5N6PHxmc-mN9vHaffL0Sc27rqahwXd6WgRxHxG95jgdoPv42tiwOgMxv2Gkxcu5ULCt1ymqBqmevGCXZ1--_n1LB1yMaSA879GIsuFqKUCV2lVeOEozo4QzkCFJq53QrlcV6ge1ZkLQQunK-lrI0AGaEyZ5y_ZAQ4qvGa80T433sk6M0EFMB4KiUqbdE2lXTBVwrLt2lgYApVTvozWRoOlNLZfTotdsLScFpt82jVZ9FE6_lb5Cy34riIF2I5_IOzsADv7L9gl7CPBxZIYwM6BG24z4BApoJadkCJbVGjNJux4VBO3L4yLt4Czg_hYWUFRHFWVSSx-vyumluQS14X5HdVBaUzHqFnCXvX43A1Jlgb1eqMSVoyQOxrzuKSb3sbg4mixqqLQb_7HJB2xxzLuuSIV4pgdrJd34S3qcGv_Lm7Xe9jGRUw
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1di9QwMOiJ4ovo-VU9JYIgiOWabpo2T7KKxyHePRwe7FtIJuneQre77u4J-3f8pc6k3fWKcC-lNJOSYb6TyQxj7-s6C6jystRKfEif-xSNcEhrBV7UqhAu9ow8O1enl_L7pJj0G27rPq1ypxOjovYLoD3yY0GF7aTOcv15-SulrlF0utq30LjL7lHpMuLqcrIPuAQyo-xPMkWljtdo2yRlD1HCV1WkemCLYsn-_xXzDcs0zJq8YYZOHrNHvf_Ixx3Bn7A7oT1k97uOkttD9uCsPyt_yv78WLRTjtF9CgsyUPzifMzRqYTYNYavuib0wUeQ9dw2DaddfN6g-HMgZljxJfX0qUPHJZ_4fDbdvc7a35Y22rhtPQ9LutnRICvzOd1mgqst_o9vyA7GlDDutpxycakjEv7lIkUHMS2Wz9jlybefX0_TviNDCugZbdCcjYTwuQSrC1k6YanajhBWgcZA11kh7ajQ6CT5zIZQCFvo3HklIA9Qq2o0es4OEKnwkvG6cCPlbO4zFWQA5aDM0XXLba0LG5ROWLajjYG-XDl1zWhMDFsqZTpyGlyCIXIanPJxP2XZ1eq4DfgLEXwPSGW244fFamp6qTWlQ7QBAvrFTlZWaAlO5qESAOChrhP2gdjFkDLAxYHt7zQgilRWy4zJnS01xrQJOxpAohDDcHjHcKZXImvzj-UT9m4_TDMpMa4Ni2uCQZ1Mh6lZwl50_LlHKa8UevdKJqwccO4A5-FIO7uKJcYxbpVlWby6fVmv2cM8SlOZCnHEDjar6_AGfbSNexsF8S9KKDtQ
  priority: 102
  providerName: ProQuest
Title Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial mesenchymal transition by sponging miR-150-5p
URI https://www.ncbi.nlm.nih.gov/pubmed/28697764
https://www.proquest.com/docview/1926249029
https://www.proquest.com/docview/1918376840
https://pubmed.ncbi.nlm.nih.gov/PMC5504775
https://doaj.org/article/7b560cce016b48a194cb42e81cccdcff
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dixMxEA_3geKL6PlVPUsEQRDX22zzsfsg0pM7DrFFioV7C0k22ytst7Xtif13_EudyW7rLR6CL2VpJmGzmcnMZCbzI-R1UcQetrw4Mhx-eJ7kEShhHxXS5ayQgtmAGTkYyosx_3wpLvfIFt6q-YCrW107xJMaL8v3P79vPoLAfwgCn8qTFegsjllBmMiViijbJ4egmBQCGgz4n6AC8GYIMnMlIy6ytAly3jpES02Fav5_79k3lFY7ofKGhjp_QO43piXt17zwkOz56ojcqcEmN0fk7qAJoz8iv77MqwkFxz9yc9RddDTsU7A3XQCUocsan97ngWQ1M2VJ8YCflrAzUId8sqQLhPspfM1A7-hsOtk-TqsfBs_gqKly6hd46aMELqczvOjkrjYwHl2jigzZYtRuKKbpIlgSjDKKwHaMxOIxGZ-ffft0ETVgDZEDo2kNmq7HWJ5wZzLBlWUGC_EwZqTLwAe2hnHTExnYT3lsvBfMiCyxuWQu8a6Qaa_3hBzApPwzQgthe9KaJI-l595J61QCVl1iikwYL7MOibdro11TyRwBNUodPJpU6no5NbyCxuXU0OXtrsuiLuPxL-JTXPAdIVbgDn_MlxPdCLRWFqbtnAeT2fLUsIw7yxOfMudc7oqiQ94gu2jkXHg5Z5rrDjBFrLil-2jpqgzc3Q45blGCfLt285bh9FY8NMMyjzyLE2h-tWvGnpgzV_n5NdLAdo1x1rhDntb8uZtSkkow_CXvENXi3Nac2y3V9CpUHweXlislnv_PF31B7iVBtlTE2DE5WC-v_Usw5ta2S_bVpeqSw9Oz4ddRNxyJdIPY_gZnzUdO
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLamIS4vCMYtMMBIICREtNh1nOQBoXKZOtb2YdqkvhnbcbpKbRLaDtS_ww_gN3JOLmUR0t72UkW1E9k6x-c7xz4-HyGvsyxwYPICXwv4ESlPfQBh52fSpiyTITMVZ-RoLAdn4tsknOyQP-1dGEyrbG1iZajTwuIe-QHDwnYiCXjysfzhI2sUnq62FBq1Why7zS8I2VYfjr6AfN9wfvj19PPAb1gFfAvovgaT3GMs5cLqJBSRYRorxjCmpU0gWDOaCd0LEwD6NNDOhUyHCTepZJY7m8kYN0DB5N8A4A0w2Ism2wCPgfKL5uSUxfJgBVgqMFsJE8zi0E862FdRBPwPBJeQsJuleQn2Du-Ru42_Svu1gt0nOy7fIzdrBsvNHrk1as7mH5DfwyKf0rzIfVsgINKTcZ-CE2srlhq6rEnvXVp1WS30fE7x1IDOwdxQi8q3pCVyCGWu1sr3dDGbto-z_KfGjT2q85S6Em-SzGHp0AXenrLnG_geXSPuVilo1Gwo5v4iAxN85cQHh9QPy4fk7Fpk9YjswqTcE0Kz0PSk0TwNpBPOSmMjDq4i11kSaicTjwStbJRtyqMjS8dcVWFSLFUtTgVDUChOBa-8275S1rVBrur8CQW-7Yhlvas_iuVUNVZCRQamba0DP9yIWLNEWCO4i5m1NrVZ5pG3qC4KjQ8MzurmDgVMEct4qT66z1ECMbRH9js9wWjYbnOrcKoxWiv1b4l55NW2Gd_ERLzcFRfYBzAAD28Djzyu9XM7JR5LiCak8EjU0dzOnLst-ey8KmkOcbKIovDp1cN6SW4PTkdDNTwaHz8jd3i1siKfsX2yu15euOfgH67Ni2pRUvL9uq3AX1qudo0
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long+non-coding+RNA+linc00673+regulated+non-small+cell+lung+cancer+proliferation%2C+migration%2C+invasion+and+epithelial+mesenchymal+transition+by+sponging+miR-150-5p&rft.jtitle=Molecular+cancer&rft.au=Lu%2C+Wei&rft.au=Zhang%2C+Honghe&rft.au=Niu%2C+Yuequn&rft.au=Wu%2C+Yongfeng&rft.date=2017-07-11&rft.issn=1476-4598&rft.eissn=1476-4598&rft.volume=16&rft.issue=1&rft_id=info:doi/10.1186%2Fs12943-017-0685-9&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12943_017_0685_9
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-4598&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-4598&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-4598&client=summon